Search Results - "Sharei, A."

Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery by Park, J.C., Bernstein, H., Loughhead, S., Zwirtes, R., Jennings, J., Nicolini, V., Klein, C., Deak, L.C., Umana, P., Trumpfheller, C., Sharei, A.

“…Cell Squeeze is a novel technology that relies on temporarily disrupting the cell membrane to deliver cargo directly into the cytosol. This approach is…”
Get full text

A PLATFORM FOR RNA-BASED AND GENOMIC CELL ENGINEERING: SIMPLIFYING MULTIPLEXED DELIVERY TO HUMAN PRIMARY IMMUNE AND STEM CELLS by Hirsch, S., Song, Z., Conover, R., Pillai, A., Larocque, A., Hanson, J., Barclay, A., Pawlak, M., Sharei, A.

“…Cell therapy has the potential to revolutionize many areas of unmet clinical needs including cancer, degenerative and metabolic diseases, genetic disorders,…”
Get full text

761P Tumor infiltrating lymphocytes expressing membrane-bound IL-2 and IL-12 exhibit enhanced proliferation, function, and persistence without requiring exogenous IL-2 support by Silver, R.J., Silva, M., Maloney, M.F., Brate, A.A., El-Sayes, N., Ozay, E.I., Parwanda, D., Bartlett, C., Sharei, A., Loughhead, S.M., Gilbert, J., Bridgen, D.T.

Get full text

39PA comparative study elucidating the substantial functional defects of electroporated T cells relative to a mechanical SQZ-based approach by Hanson, J, Cole, J, Cassereau, L, Bugge, J, Ditommaso, T, Gilbert, J, Bernstein, H, Sharei, A

Get full text

A comparative study elucidating the substantial functional defects of electroporated T cells relative to a mechanical SQZ-based approach by Hanson, J., Cole, J., Cassereau, L., Bugge, J., Ditommaso, T., Gilbert, J., Bernstein, H., Sharei, A.

Get full text

SQZing cells to rapidly generate antigen presenting cells (APC) for solid tumor immune therapies with efficient, scalable manufacturing by Loughhead, S.M., Booty, M.G., Hlavaty, K., Vicente-Suarez, A., Blagovic, K., Myint, M., Stokes, B., Yarar, D., Bernstein, H., Sharei, A.

Get full text

38PSQZing cells to rapidly generate antigen presenting cells (APC) for solid tumor immune therapies with efficient, scalable manufacturing by Loughhead, S M, Booty, M G, Hlavaty, K, Vicente-Suarez, A, Blagovic, K, Myint, M, Stokes, B, Yarar, D, Bernstein, H, Sharei, A

Get full text

183P COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors by Moser, J., Pelster, M., Jimeno, A., Park, J.C., Iams, W.T., Wise-Draper, T., Jennings, Miselis, N.R., Ji, R.R., Loughhead, S.M., Zwirtes, R., Warren, M., Sharei, A., Bernstein, H., Gordon, M.

Get full text

191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors by Jimeno, A., Miselis, N.R., Park, J.C., Jennings, J., Dhani, N., Holtick, U., Iams, W.T., Rodabaugh, K., Nair, N., Kornacker, M., Loughhead, S.M., Bernstein, H., Zwirtes, R., Ji, R.R., Warren, M., Sharei, A.

Get full text